Results 201 to 210 of about 231,925 (363)

Efficacy and Safety of ABBV‐154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b, Randomized, Placebo‐Controlled Trial

Arthritis &Rheumatology, EarlyView.
Objective Despite the availability of biologic and targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) to treat rheumatoid arthritis (RA), many patients do not experience optimized disease control. Glucocorticoids are effective but have safety risks.
Frank Buttgereit, Atul Singhal, Alan Kivitz, Edit Drescher, Yoshinori Taniguchi, Rosalía Martínez Pérez, Jaclyn Anderson, Ronilda D'Cunha, Weihan Zhao, Nicholas DeVogel, Julie Parmentier, Romy Christmann, Dilek Arikan, Howard Amital   +13 more
wiley   +1 more source

Delayed secondary glucocorticoid response elements. Unusual nucleotide motifs specify glucocorticoid receptor binding to transcribed regions of alpha 2u-globulin DNA.

, 1991
Guy C.‐K. Chan, Patrick Hess, T. Meenakshi, Jan Carlstedt‐Duke, Jan Gustafsson, Farhang Payvar   +5 more
openalex   +1 more source

Corticotropin-Releasing Factor in the Basolateral Amygdala Enhances Memory Consolidation via an Interaction with the  -Adrenoceptor-cAMP Pathway: Dependence on Glucocorticoid Receptor Activation [PDF]

, 2008
Benno Roozendaal, Gustav Schelling, J.L. McGaugh   +2 more
openalex   +1 more source

Expert Perspective: Diagnosis and Treatment of Castleman Disease

Arthritis &Rheumatology, EarlyView.
Castleman disease (CD) is a major diagnostic challenge for rheumatologists. Unicentric CD (UCD) involves one enlarged lymph node region, whereas multicentric CD (MCD) involves multiple enlarged lymph node regions. Both UCD and MCD may exhibit a wide range of symptoms that overlap with other immune‐mediated conditions.
Luke Y. C. Chen, Lu Zhang, David C. Fajgenbaum   +2 more
wiley   +1 more source

Decreased Glucocorticoid Receptor Expression and Function in Cord Blood Immune Cells from Preterm Neonates with Morbidity. [PDF]

Int J Mol Sci
Anti NAO, Deming DD, Gheorghe CP, Tugung A, Gray-Hutto N, Zhang L, Mata-Greenwood E.   +6 more
europepmc   +1 more source

Medical Treatment of Cushing’s Syndrome: Glucocorticoid Receptor Antagonists and Mifepristone [PDF]

, 2010
Frédéric Castinetti, B. Conte‐Devolx, Thierry Brue   +2 more
openalex   +1 more source

Impaired glucocorticoid receptor expression and mitochondrial metabolism in MDSCs contribute to glucocorticoid resistance in immune thrombocytopenia

, 2022
Rick Kapur
openalex   +2 more sources

Pharmacodynamic Effects of Litifilimab in Lupus in a Randomized, Placebo‐Controlled Phase 2 Study: Rapid and Sustained Reductions in Type I Interferon‐Associated Gene Expression and Cytokines

Arthritis &Rheumatology, EarlyView.
Objective The pharmacodynamic effects of litifilimab on type I interferon (IFN) response and correlations with clinical outcomes were investigated in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). Methods Participants from part A (SLE) or part B (CLE with or without SLE) of the randomized phase 2 LILAC trial who received ...
Richard Furie, Victoria P. Werth, Eric Milliman, Kyle Ferber, Roland Brown, Jad Zoghbi, Nathalie Franchimont, Youmna Lahoud, Catherine Barbey   +8 more
wiley   +1 more source

Steroids:Modulators of inflammation and immunity [PDF]

, 2010
Chapman, Karen E, Odermatt, Alex
core   +1 more source

Glucocorticoid Receptor [PDF]

, 2020
openaire   +1 more source